Project 7
Generation of hypoimmunogenic TCR or CAR cells from induced pluripotent stem cells
Prof. Dr. med. Sebastian Kobold
Abt. Klinische Pharmakologie, Klinikum der Universität München
Prof. Dr. med. Michael von Bergwelt
Medizinische Klinik III, KUM
Prof. Dr. med. Michael Hudecek
Medizinische Klinik II, UKW
PD Dr. rer. nat. Thomas Nerreter
Medizinische Klinik II, UKW
Project Summary
Chimeric antigen receptor-based immunocellular therapy has emerged as a groundbreaking advancement in the field of cancer treatment. Despite delivering remarkable clinical outcomes, therapies that rely on a patient's own cells face limitations due to extended manufacturing times, high costs, and the challenge of procuring an adequate number of cells from individuals who have undergone multiple rounds of prior chemotherapy. Off-the-shelf or allogeneic CAR cell products offer promising alternatives to address these associated challenges. Induced pluripotent stem (iPS) cells present a highly favorable cell source for cellular therapies, thanks to their unlimited capacity for proliferation, ease of genetic modification, and their ability to differentiate into immune cells, including T and NK cells. In the collaborative Baycellator project between TUM and Repairon Immuno, our shared objective is the development, production, and commercialization of iPS cell-derived immune cell products for innovative therapeutic solutions.
1. Rosenberg, S.A. and N.P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015. 348(6230): p. 62-8.
2. Iriguchi, S. and Kaneko, S., Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy. Review Cancer Sci, 2019. 110(1):16-22.
3. Li, Y. et al., Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell, 2018. 23(2):181-192.